Allegro Diagnostics, a Maynard, MA-based developer of a molecular testing platform that utilizes gene expression of normal epithelial cells in the respiratory tract to detect early signs of lung cancer, has closed a $5.4m Series A financing.
Investors include existing backers Kodiak Venture Partners and Catalyst Health Ventures.
The company intends to use the funds to support the commercialization of its lead genomic test, BronchoGen™, in 2012.
The BronchoGen™ genomic test is used in combination with standard bronchoscopy for the early diagnosis of lung cancer.
Led by President and CEO Michael D. Webb, Allegro Diagnostics is a molecular diagnostics company focused on the development and commercialization of innovative genomic tests for the diagnosis, staging and informed treatment of lung cancer and other lung diseases.